useful quick test of functional iron deficiency, but we agree with Macdougall and colleagues that further studies are required. Meanwhile, adequate oral supplements (about 300 mg/day of elemental iron) should be given; parenteral iron, with its attendant problems, should be reserved for those who cannot, or will not, take oral iron. The serum ferritin concentration should be measured monthly until the target haemoglobin concentration is achieved, followed by estimations every two to three months thereafter.

E G ANASTASSIADES J HOWARTH
HENRY M WATERS KEITH HYDE
R GOKAL

Manchester Royal Infirmary,
Manchester M13 9WL

1 Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. *BMJ* 1992;304:225-6. (25 January.)

2 Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. *BMJ* 1989;299:157-8.

3 Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO. Iron metabolism in haemodialysis patients: a study of the management of iron therapy and overload. *Q J Med* 1979;48:369-91.

4 Cook JD. Clinical evaluation of iron deficiency. *Semin Haematol* 1982;19:6-18.

Back pain and thrombolysis

SIR,—Timothy J Hendra and Andrew J Marshall report that four of the 77 elderly patients who received thrombolytic drugs in Derriford Hospital experienced back or abdominal pain.¹ Although back pain after thrombolysis has been reported before,² little is known about the frequency of its occurrence or its cause.

So far, 174 patients have received anistreplase during the Royal College of General Practitioners' myocardial infarction study, and four have subsequently experienced back pain (table). One patient's low back pain was severe enough to require the discontinuation of the injection and the administration of diamorphine and Entonox. All patients recovered within a few minutes. Interestingly, the first patient subsequently received alteplase in hospital because screening for clotting on admission gave normal results. This may support the hypothesis that back pain after thrombolysis is an allergic manifestation,² although none of the patients had any other symptoms of an allergic reaction. It would be interesting to know if any patients who had been given alteplase have experienced similar problems, since this agent is thought to produce a low allergic response.

It is worth noting that in the royal college's study two of the doctors did not think that the events were serious or related to treatment when they completed their recruitment forms, although on further questioning one doctor did wonder whether

the backache was related to treatment. Thus it is likely that half of the episodes would not have been reported to the Committee on Safety of Medicines through the yellow card scheme. This illustrates the need for the careful monitoring of any newly introduced drug and supports the rationale for the study, which is primarily a postmarketing surveillance study of anistreplase.

PHILIP HANNAFORD
CLIFFORD R KAY

Royal College of General Practitioners,
Manchester Research Unit,
Manchester M20 0TR

1 Hendra TJ, Marshall AJ. Increased prescription of thrombolytic treatment to elderly patients with suspected acute myocardial infarction associated with audit. *BMJ* 1992;304:423-5. (15 February.)

2 Shah M, Taylor RT. Low back pain associated with streptokinase. *BMJ* 1990;301:1219.

Diagnosing Alzheimer's disease

SIR,—R E Butler and colleagues suggest that single photon emission tomography is the imaging method best tolerated by elderly demented subjects.¹ As evidence they cite our work, in which 138 of 178 patients with Alzheimer's disease had computed tomography,² and their success in scanning 22 demented patients with single photon emission tomography. It would be a shame if the general medical reader was to believe this.

Our sample of 178 patients included many who were severely demented and could participate in few investigations. Many had difficulty in completing an interview and were physically disabled or behaviourally disturbed. It is not clear from what population Butler and colleagues chose their sample, but it was probably highly selected. Thus, one could say that the procedure was well tolerated in those selected to undergo it. We have carried out studies of single photon emission tomography^{3,5} and can assure readers that the intravenous injection and 15 minute scan used are less well tolerated than a non-invasive computed tomographic scan lasting about a quarter of the time.

Finally, single photon emission tomography and computed tomography measure different things (cerebral blood flow and structure, respectively) and thus should be seen as complementary and not exclusive.

A BURNS
R LEVY
R JACOBY

Section of Old Age Psychiatry,
Institute of Psychiatry,
London SE5 8AF

1 Butler RE. Diagnosing Alzheimer's disease. *BMJ* 1992;304:574-5. (29 February.)

2 Burns A, Jacoby R, Philpot M, Levy R. Computerised tomography in Alzheimer's disease. *Methods of scan analysis.*

Details of patients who experienced back pain after anistreplase was given in the community

Sex	Age (years)	Interval between onset of infarction and administration of anistreplase (hours:minutes)	Events following treatment	Timing of event in relation to anistreplase	Other treatments given	Time for pain to resolve (minutes)	GP's assessment of relation between events and anistreplase
F	41	5:10	Vomiting, backache	During injection	Diamorphine, prochlorperazine	5	Not related
F	66	4:10	Very severe lower back pain	During injection (injection discontinued)	Diamorphine,* Entonox*	10	Serious related event
M	72	4:00	Nausea and sweating for 5 minutes; pain in back for 5 minutes	5 Minutes after start of injection	Diamorphine, metoclopramide	5-10	Related event
M	74	1:10	Moderate back pain	Immediately after injection	Frusemide, Cyclimorph 15	10	Did not initially think related, but on reflection wondered if it might be

*Given for back pain.

Comparison with normal controls and clinical/radiological association. *Br J Psychiatry* 1991;159:609-14.

3 O'Brien J, Eagger S, Levy R. A study of regional cerebral blood flow and cognitive performance in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* (in press).

4 Burns A, Philpot M, Costa D, Ell P, Levy R. Investigation of dementia of the Alzheimer type with single photon emission tomography. *J Neurol Neurosurg Psychiatry* 1989;52:248-53.

5 Philpot M, Costa DC, Burns A, Ell P, Levy R. SPET in Alzheimer's disease—a follow up study. *International Journal of Geriatric Psychiatry* 1991;6:767-74.

Monitoring lithium treatment

SIR,—R F Kehoe and A J Mander report that similar patients receiving lithium are monitored by general practitioners and hospital doctors but the "stringency of lithium surveillance varies greatly among doctors" and "certain aspects of practice gave cause for concern."¹

During my training in general practice in Sidcup, Kent, a computer search of all the patients receiving repeat prescriptions for lithium showed that, out of a practice population of just under 14 000, only 15 were receiving lithium. Their ages ranged from 26 to 81.

The protocol recommended by the local psychiatrist was three monthly monitoring of lithium concentration in patients whose condition was stable. The study showed that, in 12 of the 15 patients, the lithium concentration had been measured only once in the previous six months in five patients, once in the previous year in two, and once in the previous two years in two, and three had not had their concentration checked in the previous three months, as recommended by the psychiatrist. Thirteen patients had been seen in consultations at the surgery in the previous four months, thus giving ample time for opportunistic screening. In fact, two patients had asked for their serum lithium concentration to be checked as they were worried about toxicity. It is not surprising, therefore, that "medical insurance companies report 10% of claims for negligent psychiatric practice are associated with inadequate lithium monitoring."

In view of the poor results a protocol was set up whereby patients picking up their regular three monthly prescription for lithium were sent to the practice nurse for measurement of their serum lithium concentration. Also, as recommended by the local psychiatrist, each year serum urea, electrolyte, and creatinine concentrations were measured, thyroid function tests done, and a midstream specimen of urine examined. The results were reviewed by the practitioner, who recalled the patient immediately if necessary.

Now that general practitioners are increasing their supervision of patients it is important that they are given full responsibility for setting up their own protocols for monitoring patients receiving lithium. These protocols should be suited to the needs of the clinical guidelines of the local psychiatrist. This is far better than the method used by Kehoe and Mander, whereby the chemistry laboratory sent reminders to practitioners of patients known to be receiving lithium who had not had serum concentrations estimated in the previous three months. The new protocol for monitoring patients receiving lithium in this practice will be used for medical audit in the future.

P SHARMA

Psychogeriatric Department,
Pembury Hospital,
Tunbridge Wells,
Kent TN2 4QJ

1 Kehoe RF, Mander AJ. Lithium treatment: prescribing and monitoring habits in hospital and general practice. *BMJ* 1992;304:552-4. (29 February.)

SIR,—R F Kehoe and A J Mander's advice on action to be taken when serum lithium concentrations are high was useful.¹ It did not, however, help

me with my current dilemma concerning a patient with a history of lithium toxicity with normal concentrations¹ who has recently been put back on lithium by local psychiatrists.

I question the assumption that an audit of patients taking lithium can reliably be based on those having blood tests. Surely the patients should have been identified by prescriptions for lithium preparations generated in local practices. Only one study that had done this is quoted; could the similar point prevalence of patients taking lithium be a coincidence?

My four partner practice was approached six months ago by the local psychiatric service, which asked if we would like to send any patients taking lithium to it as it was establishing a new lithium clinic. No possible benefits of this clinic for these patients were mentioned. I checked on our patients receiving lithium. Only four were taking lithium regularly; in addition, two men had received lithium in the recent past for migrainous neuralgia, one with no benefit while the other had been relieved of his symptoms and his clusters of headaches had not returned. Of the four patients receiving lithium for manic-depressive illness, two were attending the psychiatric service and two were receiving their care in general practice. The patients attending the psychiatric service had last had their lithium concentration estimated 20 months and 12 months previously and those cared for within the practice three months and two months previously.

I realise that the numbers are small, but this audit coloured my practice's view of a lithium clinic. The clinic seems to be necessary to improve the care of the patients attending the psychiatric service, but the practice prefers to carry on seeing the two others as whole people rather than send them off to become "lithium cases."

SAM ROWLANDS

Biggleswade,
Bedfordshire SG18 0PX

1 Kehoe RF, Mander AJ. Lithium treatment: prescribing and monitoring habits in hospital and general practice. *BMJ* 1992;304:552-4. (29 February.)

2 Spiers J, Hirsch SR. Severe lithium toxicity with "normal" serum concentrations. *BMJ* 1978;3:815-6.

Organ donation from intensive care units

SIR,—Sheila M Gore and colleagues suggest that kidney donation from intensive care units could be increased if there were a reduction in the non-performance of tests of brain stem function.¹ This assumes that patients who did not undergo formal testing of brain stem function were actually brain dead and suitable organ donors. We analysed our data collected during the confidential audit and cannot agree that there is necessarily an opportunity to increase kidney donation substantially in Britain.

Question 9 in the audit [was brain stem death a possible diagnosis?] was ambiguous and we suggest that some of the variability in the non-performance of testing may be due to differences in the interpretation of that question. For instance, we included all patients in whom brain stem death was a possibility, yet many of these did not undergo formal testing. One patient, for example, had had a prolonged cardiorespiratory arrest and had elective ventilation and subsequent laparotomy for a perforated viscus. Although she was comatose and apnoeic and might have had brain stem death, she died of hypotension due to septicaemia. A total of 122 patients died in our unit during the audit period; of these, 36 were classified as having a possible diagnosis of brain-stem death, although two patients were incorrectly categorised as a result of clerical errors. Only 15 of the 34 patients with a possible diagnosis of brain stem death had formal testing, and analysis of the data on the remainder

shows that four were too old to donate organs on accepted criteria, three died within two hours of admission to the intensive therapy unit, and 12 had medical conditions which made them unsuitable as organ donors. All of these 19 were severely hypoxaemic, hypotensive, and resistant to treatment, or had active supportive treatment withdrawn once it was appreciated that they were unsuitable as organ donors. Consequently formal tests were performed in 100% of those patients who were suitable for testing and who were also potential kidney donors.

Although it may be possible to increase the number of organ donors from Britain's intensive therapy units, we suggest that the potential increase is modest and that the 25% reduction in non-testing suggested by Gore and colleagues may not be achievable.

G B SMITH
G L MASTERS
C MOSS

Queen Alexandra Hospital,
Portsmouth PO6 3LY

1 Gore SM, Cable DJ, Holland AJ. Organ donation from intensive care units in England and Wales: two year confidential audit of deaths in intensive care. *BMJ* 1992;304:349-55. (8 February.)

Morphine for pain in infants

SIR,—G K Gourlay and R A Boas's paper is a reminder of the danger of respiratory depression after the administration of opiates to infants.¹

In recent years there has been renewed interest in analgesia for young infants. When neonates are referred to regional surgical units, to prevent discomfort in the ambulance it has become fashionable for junior paediatricians in the south east of England to give potent opiates. When these are given intravenously transfer is inevitably delayed while the immediate respiratory arrest is treated, but when they are given intramuscularly respiratory failure progresses relentlessly during the journey so that the infant arrives in a moribund state. Of 135 neonates referred to my care at one hospital since 1988, six have suffered severe depression of respiration or respiratory arrest as a result of this pernicious act of kindness.

R J BRERETON

Paediatric Surgical Unit,
Hospitals for Sick Children,
Great Ormond Street,
London WC1N 3JH

1 Gourlay GK, Boas RA. Fatal outcome with use of rectal morphine for postoperative pain control in an infant. *BMJ* 1992;304:766-7. (21 March.)

Measles, mumps, and rubella vaccine: time for a two stage policy?

SIR,—I strongly support Harden Carter and Dermot Gorman's views on the need for a two stage immunisation programme for measles, mumps, and rubella.¹ I recently returned from New Zealand, and the measles epidemic there is fresh in my mind.

Some 37% of the 9239 cases of measles reported in New Zealand in the second half of 1991 were among adolescents and young adults (that is, 10 to 19 year olds) and 6% of all cases were in those over 19.² Evidence suggests that failure to seroconvert or waning immunity, or both, contributed to the epidemic, particularly in these older age groups.¹ Largely as a result of this epidemic the Department of Health in New Zealand recently announced a two stage vaccination policy for measles, mumps, and rubella,³ the second dose for all schoolchildren in form 1 replacing rubella vaccine for girls in form

Percentage of cases of measles in those aged 15 and over in Argyll and Clyde Health Board, 1982-91 (with least squares regression line)

1—the same regimen that Carter and Gorman advocate.

The case for a two stage policy is formidable, being based on epidemiological facts and principles and on the experiences of other countries that have had a high uptake of immunisation for longer than the United Kingdom and are experiencing an upward shift in the age distribution of patients.⁴ The ever growing list of countries that have adopted the two stage policy makes the United Kingdom's position increasingly anomalous. Action must be taken soon if we are to defuse the "timebomb" of future epidemics of measles (and mumps) among adults⁵ with the consequent higher morbidity.^{6,7} Even now figures from Argyll and Clyde Health Board show the upward trend in the proportion of patients with measles aged 15 and over (figure).

The case for a two stage policy is, I believe, so strong that the Joint Committee on Vaccination and Immunisation should publicly give its reasons for not recommending the introduction of such a policy without delay.

D S G SLOAN

Department of Public Health,
Argyll and Clyde Health Board,
Paisley PA2 7BL

- 1 Carter H, Gorman D. Measles, mumps and rubella vaccine: time for a two stage policy? *BMJ* 1992;304:637. (7 March.)
- 2 Galloway Y, Stehr-Green P. Measles in New Zealand, 1991. *Communicable Disease New Zealand* 1991;12:167-9.
- 3 Fink JK, Ealing CA. Estimate of vaccine efficacy in a measles outbreak, College House, Palmerston North. *Communicable Disease New Zealand* 1991;12:109-12.
- 4 WHO. Expanded programme on immunisation—measles outbreak, 1989-1990, Poland. *WHO Weekly Epidemiological Record* 1992;67:50-4.
- 5 Cherry JD. The "new" epidemiology of measles and rubella. *Hosp Pract* 1980;15:49-57.
- 6 Centres for Disease Control. Update on adult immunisation. Recommendation of the immunisation practices advisory committee (ACIP). *MMWR* 1991;40(RR-12):19-20.
- 7 Giladi M, Schulman A, Kedem R, Danon YL. Measles in adults: a prospective study of 291 consecutive cases. *BMJ* 1987;295:1314.

Missing women

SIR,—The registrar general's statistics for 1841 to 1890 show that between the ages of 10 and 34 females had a higher mortality than males. Though mortality from childbearing may have played a part, deaths from tuberculosis at that time accounted for between a quarter and a fifth of all deaths and mortality from tuberculosis was much higher in women than men between the ages of 15 and 30.

The higher mortality for females in countries such as India and China, discussed in Amartya